Favorable Outcomes Combining Vedolizumab With Other Biologics or Tofacitinib for Treatment of Inflammatory Bowel Disease.
combination
tofacitinib
vedolizumab
Journal
Crohn's & colitis 360
ISSN: 2631-827X
Titre abrégé: Crohns Colitis 360
Pays: England
ID NLM: 101752188
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
30
11
2020
entrez:
13
2
2023
pubmed:
9
6
2021
medline:
9
6
2021
Statut:
epublish
Résumé
Combining advanced therapies may improve outcomes in inflammatory bowel disease (IBD), but there are little data on the effectiveness and safety of this approach. We examined outcomes of patients who received vedolizumab in combination with another biologic or tofacitinib between 2016 and 2020. Fourteen patients (10 ulcerative colitis [UC], 3 Crohn disease, 1 indeterminate colitis) received a combination of advanced therapies. Vedolizumab was combined with tofacitinib in 9 patients, ustekinumab in 3, and adalimumab in 2. Median follow-up on combination therapy was 31 weeks. Normalization of C-reactive protein (CRP) or fecal calprotectin (<5 mg/L and <150 µg/g, respectively) was achieved in 56% (5/9) and 50% (4/8) of patients. Paired median CRP decreased from 14 mg/L to <5 mg/L with combination therapy (n = 9, In this retrospective case series of a cohort with refractory IBD, combining vedolizumab with other biologics or tofacitinib improved inflammatory markers, reduced clinical disease activity and steroid use, and was well tolerated.
Sections du résumé
Background
UNASSIGNED
Combining advanced therapies may improve outcomes in inflammatory bowel disease (IBD), but there are little data on the effectiveness and safety of this approach.
Methods
UNASSIGNED
We examined outcomes of patients who received vedolizumab in combination with another biologic or tofacitinib between 2016 and 2020.
Results
UNASSIGNED
Fourteen patients (10 ulcerative colitis [UC], 3 Crohn disease, 1 indeterminate colitis) received a combination of advanced therapies. Vedolizumab was combined with tofacitinib in 9 patients, ustekinumab in 3, and adalimumab in 2. Median follow-up on combination therapy was 31 weeks. Normalization of C-reactive protein (CRP) or fecal calprotectin (<5 mg/L and <150 µg/g, respectively) was achieved in 56% (5/9) and 50% (4/8) of patients. Paired median CRP decreased from 14 mg/L to <5 mg/L with combination therapy (n = 9,
Conclusions
UNASSIGNED
In this retrospective case series of a cohort with refractory IBD, combining vedolizumab with other biologics or tofacitinib improved inflammatory markers, reduced clinical disease activity and steroid use, and was well tolerated.
Identifiants
pubmed: 36776641
doi: 10.1093/crocol/otab030
pii: otab030
pmc: PMC9802270
doi:
Types de publication
Journal Article
Langues
eng
Pagination
otab030Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.
Références
Clin Gastroenterol Hepatol. 2021 Mar;19(3):616-617
pubmed: 32068149
Clin Gastroenterol Hepatol. 2021 Jun;19(6):1303-1304
pubmed: 33248182
Aliment Pharmacol Ther. 2019 Oct;50(8):966-967
pubmed: 31591772
J Crohns Colitis. 2018 Jun 28;12(7):811-818
pubmed: 29617750
N Engl J Med. 2017 May 4;376(18):1723-1736
pubmed: 28467869
Scand J Gastroenterol. 2019 Apr;54(4):407-413
pubmed: 30945576
Biologics. 2019 Jul 30;13:139-178
pubmed: 31440029
Aliment Pharmacol Ther. 2018 Feb;47(3):364-370
pubmed: 29164650
Am J Gastroenterol. 2019 Mar;114(3):384-413
pubmed: 30840605
J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):265-7
pubmed: 17255842
Inflamm Bowel Dis. 2016 May;22(5):1209-18
pubmed: 26818425
N Engl J Med. 2012 May 17;366(20):1870-80
pubmed: 22591293
Clin Gastroenterol Hepatol. 2019 Jul;17(8):1533-1540.e2
pubmed: 30268561
N Engl J Med. 2019 Sep 26;381(13):1215-1226
pubmed: 31553834
Lancet Gastroenterol Hepatol. 2020 Jan;5(1):17-30
pubmed: 31648971
N Engl J Med. 2012 Aug 16;367(7):616-24
pubmed: 22894574
N Engl J Med. 2010 Apr 15;362(15):1383-95
pubmed: 20393175
Inflamm Bowel Dis. 2020 Jan 1;26(1):1-10
pubmed: 31112238
Aliment Pharmacol Ther. 2020 Jun;51(11):1031-1038
pubmed: 32329532
Gastroenterology. 2014 Feb;146(2):392-400.e3
pubmed: 24512909
Clin Gastroenterol Hepatol. 2015 Nov;13(11):1926-8
pubmed: 26196443
Gut. 2017 May;66(5):839-851
pubmed: 26893500
N Engl J Med. 2019 Sep 26;381(13):1201-1214
pubmed: 31553833
N Engl J Med. 2005 Dec 8;353(23):2462-76
pubmed: 16339095
Inflamm Bowel Dis. 2008 Jan;14(1):20-8
pubmed: 17973304
Inflamm Bowel Dis. 2007 Jan;13(1):2-11
pubmed: 17206633
Clin Gastroenterol Hepatol. 2021 Jun;19(6):1302-1303
pubmed: 33248087
Am J Gastroenterol. 2009 Oct;104(10):2524-33
pubmed: 19532125
Ann Rheum Dis. 2017 Jul;76(7):1253-1262
pubmed: 28143815
Gastroenterology. 2010 Oct;139(4):1147-55
pubmed: 20637205
Am J Gastroenterol. 2018 Apr;113(4):481-517
pubmed: 29610508